{"disease":{"id":"pulmonary-tuberculosis","name":"Pulmonary tuberculosis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":16,"pipeline_drug_count":1,"trial_count":4},"drugs":{"marketed":[{"drug_id":"bedaquiline","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sirturo","generic_name":"bedaquiline","company_name":"Janssen Therap","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Diarylquinoline Antimycobacterial","quality_score":75,"revenue":"400","mechanism":"Sirturo works by blocking the potassium voltage-gated channel subfamily H member 2, which is essential for the survival of Mycobacterium tuberculosis bacteria."},{"drug_id":"cycloserine","indication_name":"Active Pulmonary Tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyclorin","generic_name":"CYCLOSERINE","company_name":"Purdue Gmp","drug_phase":"marketed","molecular_target":"Glutamate receptor ionotropic, NMDA 2A","drug_class":"cycloserine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cycloserine","indication_name":"Active Extrapulmonary Tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyclorin","generic_name":"CYCLOSERINE","company_name":"Purdue Gmp","drug_phase":"marketed","molecular_target":"Glutamate receptor ionotropic, NMDA 2A","drug_class":"cycloserine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone-phosphate","indication_name":"Fulminating or disseminated pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"enviomycin","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tuberactinomycin N","generic_name":"ENVIOMYCIN","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"enviomycin","quality_score":24,"revenue":null,"mechanism":"Enviomycin works by inhibiting bacterial growth and replication."},{"drug_id":"cycloserine","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyclorin","generic_name":"CYCLOSERINE","company_name":"Purdue Gmp","drug_phase":"marketed","molecular_target":"Glutamate receptor ionotropic, NMDA 2A","drug_class":"cycloserine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"aminosalicylate-sodium","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Apacil","generic_name":"AMINOSALICYLATE SODIUM","company_name":"Consolidated Midland","drug_phase":"marketed","molecular_target":"Tyrosine-protein phosphatase non-receptor type 1","drug_class":"aminosalicylic acid","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"pyrazinamide","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pyrazinamide","generic_name":"PYRAZINAMIDE","company_name":"Dava Pharms Inc","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"Antimycobacterial [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"rifampicin","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rifadin","generic_name":"Rifampicin","company_name":"Sanofi Aventis Us","drug_phase":"marketed","molecular_target":"Solute carrier organic anion transporter family member 1A2, ATP-binding cassette sub-family G member 2, Alpha-synuclein","drug_class":"Rifamycin Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"isoniazid","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isoniazid","generic_name":"ISONIAZID","company_name":"Epic Pharma Llc","drug_phase":"marketed","molecular_target":"Myeloperoxidase","drug_class":"Antimycobacterial [EPC]","quality_score":69,"revenue":null,"mechanism":"Isoniazid works by inhibiting the enzyme myeloperoxidase, which is essential for the survival of Mycobacterium tuberculosis."},{"drug_id":"rifapentine","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Priftin","generic_name":"RIFAPENTINE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"","drug_class":"Rifamycin Antimycobacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Priftin works by inhibiting the synthesis of mycolic acid, a key component of the Mycobacterium tuberculosis cell wall."},{"drug_id":"isoniazide","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"isoniazide","company_name":"Bridge BioResearch Ltd.","drug_phase":"phase_2","molecular_target":"Myeloperoxidase, Cytochrome P450 3A4, Cytochrome P450 3A5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"thioacetazone","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"thioacetazone","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"aminosalicylic-acid-resin-complex","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"REZIPAS","generic_name":"AMINOSALICYLIC ACID RESIN COMPLEX","company_name":"BRISTOL MYERS SQUIBB","drug_phase":"marketed","molecular_target":"Tyrosine-protein phosphatase non-receptor type 1, Cyclooxygenase, 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"ethambutol","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Myambutol","generic_name":"ETHAMBUTOL","company_name":"Kanchan Hlthcare","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"Antimycobacterial","quality_score":48,"revenue":null,"mechanism":""},{"drug_id":"ethionamide","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trecator","generic_name":"ETHIONAMIDE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Antimycobacterial","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aminosalicylic-acid","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Apacil","generic_name":"AMINOSALICYLIC ACID","company_name":"Consolidated Midland","drug_phase":"marketed","molecular_target":"Tyrosine-protein phosphatase non-receptor type 1","drug_class":"aminosalicylic acid","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"capreomycin","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Capastat Sulfate","generic_name":"CAPREOMYCIN","company_name":"Epic Pharma Llc","drug_phase":"marketed","molecular_target":"","drug_class":"Antimycobacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"seromycin","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"seromycin","company_name":"Massachusetts General Hospital","drug_phase":"discontinued","molecular_target":"Cytochrome P450 3A4, Glutamate receptor ionotropic, NMDA 1, Glutamate receptor ionotropic, NMDA 2A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"prednisone","indication_name":"Fulminating or disseminated pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"rifampin","indication_name":"Pulmonary Tuberculosis","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RIFAMPIN","company_name":"","drug_phase":"marketed","molecular_target":"DNA-dependent RNA polymerase","drug_class":"Rifamycin Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Rifampin inhibits DNA-dependent RNA polymerase activity in susceptible Mycobacterium tuberculosis organisms."}],"offLabel":[],"totalMarketed":20,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT03044158","title":"GeneXpert Performance Evaluation for Linkage to Tuberculosis Care","phase":"NA","overall_status":"COMPLETED","enrollment_count":10644,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT06528418","title":"Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"ChromX Health","has_results":false},{"nct_id":"NCT04433195","title":"Xpert MTB/RIF Test in the Diagnosis of Pulmonary Tuberculosis","phase":"NA","overall_status":"UNKNOWN","enrollment_count":6900,"lead_sponsor_name":"Taipei Medical University WanFang Hospital","has_results":false},{"nct_id":"NCT06114628","title":"Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT05756582","title":"Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students","phase":"","overall_status":"RECRUITING","enrollment_count":2040,"lead_sponsor_name":"Eleonora Nucera","has_results":false},{"nct_id":"NCT05268380","title":"Collision of Three Global Pandemics: the Effect of Tuberculosis and HIV on the Epidemiological, Clinical, Virological and Immunological Trajectory of COVID-19 in Botswana and Namibia","phase":"","overall_status":"COMPLETED","enrollment_count":1750,"lead_sponsor_name":"University of Namibia","has_results":false},{"nct_id":"NCT05337163","title":"A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China","phase":"","overall_status":"COMPLETED","enrollment_count":1564,"lead_sponsor_name":"Creative Biosciences (Guangzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT04666311","title":"Diagnostic Accuracy of CAD4TB and C-reactive Protein Assay as Triage Tests for Pulmonary Tuberculosis","phase":"","overall_status":"COMPLETED","enrollment_count":1400,"lead_sponsor_name":"Klaus Reither","has_results":false},{"nct_id":"NCT03350048","title":"Evaluation of Host Biomarker-based Point-of-care Tests for Targeted Screening for Active TB","phase":"","overall_status":"COMPLETED","enrollment_count":969,"lead_sponsor_name":"Prof Gerhard Walzl","has_results":false},{"nct_id":"NCT02821832","title":"Using Biomarkers to Predict TB Treatment Duration","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":946,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT05236452","title":"Effect of Integrating Traditional Tuberculosis Care With Modern Health Care on Case Detection","phase":"NA","overall_status":"COMPLETED","enrollment_count":918,"lead_sponsor_name":"Bahir Dar University","has_results":false},{"nct_id":"NCT05477966","title":"A Retrospective Cohort Study to Develop Markers for TB Severity and Treatment Progress","phase":"","overall_status":"UNKNOWN","enrollment_count":900,"lead_sponsor_name":"Jae-Joon Yim","has_results":false},{"nct_id":"NCT06253715","title":"Shortened Regimen for Drug-susceptible TB in Children","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":860,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT03728725","title":"Xpert MTB/XDR Clinical Evaluation Trial","phase":"","overall_status":"COMPLETED","enrollment_count":710,"lead_sponsor_name":"Foundation for Innovative New Diagnostics, Switzerland","has_results":false},{"nct_id":"NCT06457269","title":"Evaluating the Potential of Large Language Models for Respiratory Disease Consultations","phase":"NA","overall_status":"COMPLETED","enrollment_count":703,"lead_sponsor_name":"North Sichuan Medical College","has_results":false},{"nct_id":"NCT02581527","title":"A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":672,"lead_sponsor_name":"St George's, University of London","has_results":false},{"nct_id":"NCT02467608","title":"Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":557,"lead_sponsor_name":"Orient Pharma Co., Ltd.","has_results":false},{"nct_id":"NCT07209761","title":"A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":532,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":false},{"nct_id":"NCT03822156","title":"Clinical Analysis of the Patients With Cavitary Pulmonary TB and Endobronchial TB in the PPM-UUH Cohort","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"University of Ulsan","has_results":false},{"nct_id":"NCT00685360","title":"A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":481,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":true},{"nct_id":"NCT03338621","title":"Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":455,"lead_sponsor_name":"Global Alliance for TB Drug Development","has_results":true},{"nct_id":"NCT05824871","title":"A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Shanghai Jiatan Pharmatech Co., Ltd","has_results":false},{"nct_id":"NCT06199921","title":"ATORvastatin in Pulmonary TUBerculosis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":440,"lead_sponsor_name":"Obafemi Awolowo University Teaching Hospital","has_results":false},{"nct_id":"NCT04938596","title":"Airborne Preventive Measures to Reduce New TB Infections in Household Contacts","phase":"NA","overall_status":"COMPLETED","enrollment_count":432,"lead_sponsor_name":"Pontificia Universidad Catolica de Chile","has_results":false},{"nct_id":"NCT04122404","title":"POC Strategies to Improve TB Care in Advanced HIV Disease","phase":"NA","overall_status":"COMPLETED","enrollment_count":425,"lead_sponsor_name":"University of Southern Denmark","has_results":false},{"nct_id":"NCT05807399","title":"PanACEA - STEP2C -01","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":390,"lead_sponsor_name":"Michael Hoelscher","has_results":false},{"nct_id":"NCT02106039","title":"Pulmonary Tuberculosis Patients With Diabetes Mellitus","phase":"NA","overall_status":"COMPLETED","enrollment_count":350,"lead_sponsor_name":"Universitas Padjadjaran","has_results":false},{"nct_id":"NCT06192160","title":"Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":315,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT07076225","title":"Ultra-Short Regimen for Elderly DS-TB","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Shenzhen Third People's Hospital","has_results":false},{"nct_id":"NCT05766267","title":"Short-course Regimens for the Treatment of Pulmonary Tuberculosis","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":288,"lead_sponsor_name":"Centers for Disease Control and Prevention","has_results":false},{"nct_id":"NCT04187469","title":"Efficacy and Safety of Isoniazid, Rifampicin and Moxifloxacin for the Intensive Phase of Initial Therapy of PTB","phase":"NA","overall_status":"UNKNOWN","enrollment_count":286,"lead_sponsor_name":"Fifth Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06727864","title":"Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":270,"lead_sponsor_name":"Kaohsiung Veterans General Hospital.","has_results":false},{"nct_id":"NCT02371681","title":"NexGen EBA Radiologic and Immunologic Biomarkers of Sterilizing Drug Activity in Tuberculosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":262,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT06922916","title":"Perioperative Risk Factors Related to the Prognosis of Lung Transplantation: A Retrospective Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":250,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT05148949","title":"Study on Three Doses of an Inactivated COVID-19 Vaccine in Chinese Pulmonary Tuberculosis Patients","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":240,"lead_sponsor_name":"Jiangsu Province Centers for Disease Control and Prevention","has_results":false},{"nct_id":"NCT04081077","title":"PRACTECAL-PKPD Sub Study","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":240,"lead_sponsor_name":"Medecins Sans Frontieres, Netherlands","has_results":false},{"nct_id":"NCT06157034","title":"Prokinetic Effect of Selected Nutraceuticals","phase":"NA","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Allama Iqbal Open University Islamabad","has_results":false},{"nct_id":"NCT05045391","title":"Pulmonary Aspergillosis in Tuberculosis Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan","has_results":false},{"nct_id":"NCT06081361","title":"Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":186,"lead_sponsor_name":"Beijing Chest Hospital","has_results":false},{"nct_id":"NCT03086486","title":"Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":181,"lead_sponsor_name":"Global Alliance for TB Drug Development","has_results":true},{"nct_id":"NCT07517445","title":"Bactericidal Activity and Safety of Nicotinamide in Combination With Bedaquiline, Pretomanid, and Linezolid in Drug-susceptible Pulmonary Tuberculosis","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":165,"lead_sponsor_name":"Gates Medical Research Institute","has_results":false},{"nct_id":"NCT02256696","title":"Assessing PA-824 for Tuberculosis (the APT Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":157,"lead_sponsor_name":"Johns Hopkins University","has_results":true},{"nct_id":"NCT04504851","title":"Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":154,"lead_sponsor_name":"National University Hospital, Singapore","has_results":false},{"nct_id":"NCT06875336","title":"A Multicentric Cohort and Biomarker Study for Improved Care of Patients with Extrapulmonary Tuberculosis","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"University of Cologne","has_results":false},{"nct_id":"NCT04721795","title":"Treating Tuberculosis With the Lipid Lowering Drug Atorvastatin in Nigeria(ATORvastatin in Pulmonary TUBerculosis)","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Obafemi Awolowo University Teaching Hospital","has_results":false},{"nct_id":"NCT07525427","title":"Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Gates Medical Research Institute","has_results":false},{"nct_id":"NCT06845618","title":"Blood Tuberculosis DNA Levels to Monitor Tuberculosis Treatment","phase":"","overall_status":"RECRUITING","enrollment_count":140,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT04493671","title":"Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":137,"lead_sponsor_name":"Global Alliance for TB Drug Development","has_results":false},{"nct_id":"NCT01252992","title":"Paradoxical Reactions in Non Immuno-compromized Patients With Extrapulmonary Tuberculosis","phase":"","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05896930","title":"Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":134,"lead_sponsor_name":"TASK Applied Science","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}